openPR Logo
Press release

Gunshot Injuries Treatment Market Growing Continuously, By Product (XStat, Airwrap, Floseal), and Geography - Insights, Size, Share, Opportunity Analysis, and Industry Forecast till 2025

09-18-2018 05:31 PM CET | Health & Medicine

Press release from: Coherent Market Insights - Pharmaceutical Industry

Gunshot Injuries Treatment

Gunshot Injuries Treatment

Traumatic injury remains a persistent and significant public health problem, which poses as a major factor driving demand for gunshot injuries treatment. According to the Centers for Disease Control and Prevention, around 84,000 gun-shot related injuries and around 2 million knife related injuries were recorded in 2013, globally. The injuries cause deep hemorrhagic wounds, which are characterized by profuse bleeding from the ruptured blood vessels. Stats released by the Food and Drug Administration,2015, has predicted that the deaths due to gunshot or traumatic injuries is expected to account for 30-40% of civilian deaths, often before the patient reaches the hospital.

Ask for SAMPLE copy of this business report : https://www.coherentmarketinsights.com/insight/request-sample/772

The global gunshot injuries treatment market was valued at US$ 8.0 million in 2017 and is expected to witness a CAGR of 8.2% over the forecast period (2017 – 2025).
It further revealed that the innovative FDA approved Xstat would possibly make a difference to prevent mortality, if made available to the emergency personnel to prevent delay in care, as hospital care cannot be accessed immediately. North America is expected to hold a dominant position in the gunshot injuries treatment market, attributed to the availability of advanced and FDA approved products such as sponge-filled syringe and bandages. According to data published in Trauma Reports in 2012, penetrating trauma is the second major cause of injury-related deaths, with an around 60,000 - 80,000 occurrence rate of nonfatal gunshot, in the U.S.

FDA approval of the gunshot injuries treatment products is a prominent factor fueling the gunshot injuries treatment market

Advancements in medicine and technology help prevent the mortality rate associated with gunshot injuries, thus augmenting the demand for these preventive and efficient products. Xstat is the only gunshot wound management device, which is extensively used on battlefields, globally. XStat was manufactured by RevMedx and approved by the FDA in April, 2014, to plug up life-threatening wounds. Furthermore, the launch and availability of these devices is expected to propel the market in Asia Pacific and Europe. The clearance of the Xstat 30 for gunshot injury treatment expands the device’s indication for use for adults and adolescents in the general population, thereby facilitating the market growth. XStat 30 was FDA-approved in December 2015, for use for patients with high life-threatening risk, suffering from immediate and severe hemorrhagic shocks when definitive care at an emergency care facility cannot be achieved within minutes. 

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com
Visit Our New Website : https://www.coherentwire.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gunshot Injuries Treatment Market Growing Continuously, By Product (XStat, Airwrap, Floseal), and Geography - Insights, Size, Share, Opportunity Analysis, and Industry Forecast till 2025 here

News-ID: 1246396 • Views:

More Releases from Coherent Market Insights - Pharmaceutical Industry

Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 2026 : Key Players are Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Inc., Pfizer, Inc., Actelion Pharmaceuticals
Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Ask For Sample Copy of Research
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2026
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development. Ask For a Sample Copy of This Business Report @
Cannabis Testing Services Market: New Business Opportunities and Investment Research Report 2018-2026
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976 Market
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insignificant CAGR Till 2025 With Top Players Novartis AG, Celgene Corp, Otsuka Pharmaceutical Co., Sandoz, Dr Reddys Laboratories, Pharmascience
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around

All 5 Releases


More Releases for FDA

DreaMed receives 5th FDA Clearance
TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes
FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30). Announcing New Design Control Training Courses Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation. GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet
11-09-2016 | Science & Education
GRCTS
FDA online training
Description: Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding